---
title: "Takeda Pharmaceutical Company: Revenue up 10.2% on FX tailwinds; core profit flat at CER; FY2026 outlook cautious"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294316876.md"
description: "Revenue rose 10.2% year-over-year to JPY 1,219.9 billion, driven by yen depreciation, while core revenue was flat at constant exchange rates. Operating profit increased, but net profit declined due to higher tax and restructuring costs. FY2026 guidance expects modest revenue growth but lower core profit andriginal document: Takeda Pharmaceutical Co. Ltd. [4502] Interim report — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T07:03:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294316876.md)
  - [en](https://longbridge.com/en/news/294316876.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294316876.md)
---

# Takeda Pharmaceutical Company: Revenue up 10.2% on FX tailwinds; core profit flat at CER; FY2026 outlook cautious

Revenue rose 10.2% year-over-year to JPY 1,219.9 billion, driven by yen depreciation, while core revenue was flat at constant exchange rates. Operating profit increased, but net profit declined due to higher tax and restructuring costs. FY2026 guidance expects modest revenue growth but lower core profit and EPS.

Original document: Takeda Pharmaceutical Co. Ltd. \[4502\] Interim report — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda Insiders Sold Shares Worth Over $3.2M](https://longbridge.com/en/news/295729897.md)
- [Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock](https://longbridge.com/en/news/295785108.md)
- [Takeda Pharmaceutical Insiders Sold Shares Worth Over $3.5M](https://longbridge.com/en/news/295731657.md)
- [Should FDA Approval of ORZEYFUL for Narcolepsy Type 1 Prompt Action From Takeda Pharmaceutical (TSE:4502) Investors?](https://longbridge.com/en/news/295300131.md)
- [Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’](https://longbridge.com/en/news/295770785.md)